Tempus AI, Inc. (BMV:TEM)
Mexico · Delayed Price · Currency is MXN | Market Cap | 144.88B -27.3% |
| Revenue (ttm) | 24.59B +69.8% |
| Net Income | -5.46B |
| EPS | -31.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,974 |
| Average Volume | 1,042 |
| Open | 800.00 |
| Previous Close | 790.00 |
| Day's Range | 800.00 - 805.00 |
| 52-Week Range | 735.01 - 1,905.00 |
| Beta | n/a |
| RSI | 44.15 |
| Earnings Date | May 5, 2026 |
About Tempus AI
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]
Financial Performance
In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.
Financial numbers in USD Financial StatementsNews
Tempus AI announces clinical launch of ArteraAI Prostate Test
Tempus AI (TEM) announced the clinical launch of the ArteraAI Prostate Test. The CLIA-certified and CAP-accredited prognostic test will be fully integrated into the Tempus platform, providing urologis...
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and...
Tempus AI announces strategic collaboration with Bristol Myers
Tempus AI (TEM) announced a new initiative with Bristol Myers Squibb (BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial de...
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE...
Cathie Wood’s ARK Investment buys 163K shares of Tempus AI today
20:02 EDT Cathie Wood’s ARK Investment buys 163K shares of Tempus AI (TEM) today
Tempus AI price target lowered to $64 from $95 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Tempus AI (TEM) to $64 from $95 and keeps a Buy rating on the shares. The firm cites the…
Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced that its CARE Program (Compr...
Tempus AI price target lowered to $80 from $90 at BTIG
BTIG lowered the firm’s price target on Tempus AI (TEM) to $80 from $90 and keeps a Buy rating on the shares. The firm cites a pullback in valuations in…
Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $400....
Tempus AI announces proposed convertible senior notes offering
Tempus AI (TEM) announced its intent to offer, subject to market conditions and other factors, $350.0 million aggregate principal amount of Convertible Senior Notes due in 2032 in a private…
Cathie Wood’s ARK Investment buys 146K shares of Tempus AI today
20:02 EDT Cathie Wood’s ARK Investment buys 146K shares of Tempus AI (TEM) today
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer,...
Tempus AI price target lowered to $59 from $68 at Baird
Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Tempus AI (TEM) to $59 from $68 and keeps an Outperform rating on the shares. The firm updated its…
Tempus AI price target raised to $68 from $65 at TD Cowen
TD Cowen raised the firm’s price target on Tempus AI (TEM) to $68 from $65 and keeps a Buy rating on the shares. The firm said its strong growth was…
Lucent Diagnostics announces collaboration with Tempus AI
Lucent Diagnostics, a brand of Quanterix Corporation (QTRX), announced a collaboration with Tempus AI (TEM) to broaden access to a novel blood-based biomarker panel designed to improve detection accur...
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading ...
Tempus AI reports Q1 adjusted EPS (13c), consensus (20c)
Reports Q1 revenue $348.1M, consensus $345.44M. “Our strong financial and operational performance this quarter underscores the accelerating demand for our AI-driven diagnostic platform and the immense...
Tempus AI raises FY26 revenue view to $1.59B-$1.6B from $1.59B, consensus $1.59B
Backs FY26 adjusted EBITDA view roughly $65M.
Tempus AI Earnings Call Transcript: Q1 2026
Revenue grew 36% year-over-year to $348.1 million, led by strong oncology and data businesses. Guidance was raised to $1.59–$1.6 billion in revenue and $65 million adjusted EBITDA for 2026, with robust growth in strategic pharma collaborations and improving cash flow expected.
Tempus AI Earnings release: Q1 2026
Tempus AI released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Tempus AI Slides: Q1 2026
Tempus AI has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Tempus AI Quarterly report: Q1 2026
Tempus AI has published its Q1 2026 quarterly earnings report on May 5, 2026.
Tempus Reports First Quarter 2026 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...
Tempus to Host Inaugural Investor Day on May 29, 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the company will host an Investor Day on Fr...
Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, today announced it has been nam...